Effect of one-year lumacaftor–ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients

• Published in: Journal of cystic fibrosis 2020-09, Vol.19 (5), p.712-716
• Main Authors: Misgault, Bastien, Chatron, Eva, Reynaud, Quitterie, Touzet, Sandrine, Abely, Michel, Melly, Laurent, Dominique, Stéphane, Troussier, Françoise, Ronsin-Pradel, Olivia, Gerardin, Michèle, Mankikian, Julie, Cosson, Laure, Chiron, Raphael, Bounyar, Leila, Porzio, Michel, Durieu, Isabelle, Weiss, Laurence, Kessler, Romain, Kessler, Laurence
• Format: Article
• Language: English
• Subjects: CFTR corrector and potentiator; Cystic fibrosis; Glucose tolerance abnormalities; Life Sciences; OGTT
• ISSN: 1569-1993; 1873-5010
• DOI: 10.1016/j.jcf.2020.03.002

•Lumacaftor-ivacaftor's impact on glucose tolerance in CF patients homozygous for Phe508del CFTR.•Comparison between pre- and 1-year post-treatment outcomes in 40 CF patients.•Glucose tolerance is improved in more than half of treated CF patients. To investigate the effects of 1-year lumacaftor–ivacaftor treatment on abnormalities in glucose tolerance (AGT) in Phe508del homozygous cystic fibrosis (CF) patients. Untreated CF patients with glucose intolerance or newly diagnosed diabetes were included in a prospective, observational study. After 1-year lumacaftor-ivacaftor treatment, AGT were evaluated by using oral glucose tolerance test. Forty patients participated. 78% of patients had glucose intolerance and 22% diabetes at baseline. After one-year treatment, 50% of patients had normal glucose tolerance, 40% glucose intolerance, and 10% diabetes (p